MedTrace Logo

12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder

NCT01316302 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2016-10-17

Study results available
· View outcomes & findings →

Summary

This study is designed to evaluate the efficacy and safety of Pristiq® in treatment of the symptoms of Generalized Social Anxiety Disorder (SAD).

Conditions

Interventions

DRUG

Pristiq

Flexible dose, 50-100mg QD, for 12 weeks.

DRUG

Placebo

Matching placebo, taken QD for 12 weeks.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • The Medical Research Network

    lead OTHER

Principal Investigators

  • Michael R. Liebowitz, MD · The Medical Research Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-11-30
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01316302 on ClinicalTrials.gov